Insights On CONTRACT PHARMA MANUFACTURING

  1. The Costs Of Disengagement From China 3/12/2025

    If we ever did implement (suffer through?) some rather large-scale “disengagement” between the U.S. and China in the biopharma industry realm, what costs would we incur?

  2. Back To Supply-Chain And Outsourcing Basics 3/12/2025

    Vince Kosewski, KALA BIO, and Kishore Hotha, Dr. Hotha’s Life Sciences, remind us that our recent outsourcing fears should remind us of the fundamentals for approaching supply-chain decision-making.

  3. The BIOSECURE Act Will Be Back… With A Dose Of Tariffs! 3/12/2025

    Biopharma executives Robert Discordia, CEO, Equulus Therapeutics, and Reza Oliyai, CEO, Oliyai Consulting, agree we may not have seen the last of the Act… or tariffs to compound industry challenges.

  4. Update On BIOSECURE Act… And Other Supply-Chain Concerns 3/12/2025

    Chief Editor Louis Garguilo provides a succinct update on the Act, and broadens the discussion to other challenges on the horizon.

  5. Future-Proofing Life Sciences Manufacturing: 2025 CDMO Trends 3/12/2025

    Review contract manufacturing's evolution, driven by technological advancements and regulatory changes, and how CMOs and CDMOs are navigating opportunities and challenges.

  6. Our Analytical And Quality Control Strategy For Your Therapies 3/12/2025

    A comprehensive Quality Risk Analysis and Control Strategy is built on five key pillars, each playing a vital role in ensuring that every final product meets the highest safety and efficacy standards.

  7. Best Practices For Oncolytic Virus Design, Development, Manufacturing 3/12/2025

    Oncolytic viruses have the potential to revolutionize standard cancer treatment, but their continued progress hinges on meeting a number of goals linked to safety, efficacy, and commercial scale-up.

  8. Synergies Between Vaccine Expertise On Developing, Manufacturing C&G Products 3/11/2025

    Understanding these synergies and their impact on efficiency, safety, and cost-effectiveness is essential for stakeholders navigating the complexities of CGT development and production.

  9. Strategies For Engineering Mammalian Cells To Express Difficult Proteins 3/11/2025

    By leveraging cells equipped with an existing TARGATT™ landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.

  10. Strategies For Engineering Mammalian Cells 3/11/2025

    Using cells with a pre-engineered TARGATT™ landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.